Stryker Company Profile (NYSE:SYK)

Stryker trades on the New York Stock Exchange (NYSE) under the ticker symbol "SYK."

Stryker declared a quarterly dividend on Thursday, August 3rd. Shareholders of record on Friday, September 29th will be paid a dividend of $0.425 per share on Tuesday, October 31st. This represents a $1.70 dividend on an annualized basis and a yield of 1.21%. The ex-dividend date is Thursday, September 28th. View Stryker's Dividend History.

Stryker Co. (NYSE:SYK) posted its quarterly earnings data on Thursday, July, 27th. The company reported $1.53 EPS for the quarter, topping the Zacks' consensus estimate of $1.51 by $0.02. The company had revenue of $3.01 billion for the quarter, compared to analyst estimates of $2.98 billion. Stryker had a return on equity of 15.89% and a net margin of 12.98%. The business's revenue was up 6.1% compared to the same quarter last year. During the same period in the prior year, the company earned $1.39 EPS. View Stryker's Earnings History.

Stryker is scheduled to release their next quarterly earnings announcement on Thursday, October, 26th 2017. View Earnings Estimates for Stryker.

Stryker issued an update on its FY17 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of $6.45-6.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.43. Stryker also updated its Q3 guidance to $1.50-1.55 EPS.

20 analysts have issued 1-year target prices for Stryker's stock. Their forecasts range from $125.00 to $160.00. On average, they expect Stryker's share price to reach $145.31 in the next year. View Analyst Ratings for Stryker.

Here are some recent quotes from research analysts about Stryker stock:

• 1. Needham & Company LLC analysts commented, "We are upgrading SYK shares to Hold from Underperform since our thesis is not playing out as expected. SYK also announced a voluntary product recall and ship hold in its Sage Products business earlier this week. The recall was due to a cross-contamination issue with its Oral Care products and the ship hold was due to a new test required by the FDA." (8/25/2017)
• 2. According to Zacks Investment Research, "Stryker exited the second quarter on a solid note, beating the Zacks Consensus Estimate on both counts. Solid performance in the MAKO platform drove revenues. An upbeat guidance for the full year instills investor confidence on the stock. Stryker has a diversified product portfolio. Continued strong demand for hemorrhagic and ischemic stroke products and neuro-powered instruments boosted sales in the neurotechnology segment. Stryker has had an impressive run on the bourse over the last one year, trading above the broader industry. However, volatility in foreign currency exchange is likely to impede revenue growth. Stryker also faces supply-side headwinds and has been grappling with issues in the spine business for long. Also, China might prove to be a challenging market." (8/23/2017)

Some companies that are related to Stryker include Smith & Nephew SNATS (SNN), Smith & Nephew plc (SN), Glaukos Corporation (GKOS), Endologix (ELGX), Cerus Corporation (CERS), RTI Surgical (RTIX), Obalon Therptcs (OBLN), ConforMIS (CFMS), Second Sight Medical Products (EYES), Concepta PLC (CPT), Concepta PLC (FRI), Cyberonics (CYBX), HeartWare International (HTWR), St Jude Medical (STJ), Trivascular Technologies (TRIV) and Uroplasty (UPI).

Stryker's management team includes the folowing people:

• Kevin A. Lobo, Chairman of the Board, President, Chief Executive Officer
• Glenn S. Boehnlein, Chief Financial Officer, Vice President
• Lonny J. Carpenter, Group President - Global Quality and Business Operations
• David K. Floyd, Group President - Orthopaedics
• Graham A. Mclean, President, Asia-Pacific
• Timothy J. Scannell, Group President - MedSurg and Neurotechnology
• M. Kathryn Fink, Chief Human Resource Officer, Vice President
• William E. Berry Jr., Principal Accounting Officer, Vice President, Corporate Controller
• Bijoy S.N. Sagar, Chief Information Officer, Vice President
• Katherine A. Owen, Vice President - Strategy and Investor Relations

Stryker's stock is owned by many different of institutional and retail investors. Top institutional investors include Capital Research Global Investors (8.23%), Greenleaf Trust (6.48%), Vanguard Group Inc. (6.44%), BlackRock Inc. (6.18%), State Street Corp (3.60%) and Franklin Resources Inc. (3.05%). Company insiders that own Stryker stock include David Floyd, Glenn S Boehnlein, Graham A Mclean, Howard E Cox Jr, Katherine Ann Owen, Kevin Lobo, Lonny J Carpenter, Louise Francesconi, Roch Doliveux, Ronda E Stryker, Srikant Datar, Timothy J Scannell, William E Berry Jr and Yin C Becker. View Institutional Ownership Trends for Stryker.

Stryker's stock was sold by a variety of institutional investors in the last quarter, including Greenleaf Trust, Franklin Resources Inc., Lazard Asset Management LLC, Bank of New York Mellon Corp, SG Americas Securities LLC, Capital Research Global Investors, The Manufacturers Life Insurance Company and FMR LLC. Company insiders that have sold Stryker stock in the last year include David Floyd, Graham A Mclean, Kevin Lobo, Lonny J Carpenter, Louise Francesconi, Ronda E Stryker, Timothy J Scannell and Yin C Becker. View Insider Buying and Selling for Stryker.

Stryker's stock was bought by a variety of institutional investors in the last quarter, including Koch Industries Inc., BlackRock Inc., Janus Henderson Group PLC, Vanguard Group Inc., State Treasurer State of Michigan, JPMorgan Chase & Co., Jensen Investment Management Inc. and Swiss National Bank. View Insider Buying and Selling for Stryker.

Shares of Stryker can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Stryker stock can currently be purchased for approximately $140.89.